News
-
-
-
PRESS RELEASE
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announces positive interim results of obefazimod in ulcerative colitis patients after 2 years, showing maintenance of remission and safety profile consistency -
-
-
PRESS RELEASE
EQS-Adhoc: LANXESS Aktiengesellschaft: LANXESS signs contract to sell Urethane Systems business to UBE Corporation
LANXESS signs contract to sell Urethane Systems business to UBE Corporation for €460m, using proceeds to reduce net financial debt. Transaction subject to regulatory approval, expected to close in H1 2025 -
-
-
-